-
Mashup Score: 27Merck to Acquire Caraway Therapeutics, Inc. - Merck.com - 5 month(s) ago
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. The upfront payment will be expensed by Merck in the fourth quarter of 2023 and included in non-GAAP results. “Caraway’s multidisciplinary approach has yielded important progress in evaluating novel mechanisms of modulation of lysosomal function with potential for the treatment of progressive neurodegenerative diseases,” said George Addona, senior vice president, discovery, preclinical development and translational medicine, Merck Research Laboratories. “We look forward to applying our
Source: www.merck.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 23 Key Updates in Alzheimer’s Disease Research - 7 month(s) ago
Novel insights into Alzheimer’s disease risk including the complex role of cholesterol, the protein ABCA7, and nighttime hot flashes.
Source: www.psychiatrist.comCategories: Latest Headlines, PsychiatryTweet
-
Mashup Score: 73 Key Updates in Alzheimer’s Disease Research - 7 month(s) ago
Novel insights into Alzheimer’s disease risk including the complex role of cholesterol, the protein ABCA7, and nighttime hot flashes.
Source: www.psychiatrist.comCategories: Latest Headlines, PsychiatryTweet
-
Mashup Score: 1Basic & Clinical Pharmacology & Toxicology - 8 month(s) ago
International Journal of Geriatric Psychiatry and Basic & Clinical Pharmacology & Toxicology are jointly calling for papers on advances in the neurobiology and treatment of neurodegenerative disorders. This special issue has an intentionally broad topic and welcomes clinical, preclinical, and translational original research papers, as well as systematic and literature reviews. We accept a wide variety of types of studies, including (but not limited to): pathophysiological aspects, pilot studies, clinical
Source: onlinelibrary.wiley.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Sleep Features and Long-Term Incident Neurodegenerative Diseases: A Polysomnographic Study - 8 month(s) ago
The most prevalent neurodegenerative diseases (NDD) are Alzheimer’s disease and Parkinson’s disease, affecting 43.3 and…
Source: www.emjreviews.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0AI-driven eye scans detect signs of Parkinson's disease early on - 8 month(s) ago
“Finding signs of a number of diseases before symptoms emerge means that, in the future, clinicians could delay the onset and impact of lifechanging neurodegenerative disorders,” one of the
Source: www.healthcareitnews.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1Basic & Clinical Pharmacology & Toxicology - 9 month(s) ago
International Journal of Geriatric Psychiatry and Basic & Clinical Pharmacology & Toxicology are jointly calling for papers on advances in the neurobiology and treatment of neurodegenerative disorders. This special issue has an intentionally broad topic and welcomes clinical, preclinical, and translational original research papers, as well as systematic and literature reviews. We accept a wide variety of types of studies, including (but not limited to): pathophysiological aspects, pilot studies, clinical
Source: onlinelibrary.wiley.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
The multiple sclerosis-focused company will use the funds to speed up the company’s commercialization efforts.
Source: www.mobihealthnews.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 6Understanding Causes of Devastating Neurodegenerative Condition Affecting Children - 10 month(s) ago
A common theme among parents and family members caring for a child with the rare Batten disease is “love, hope, cure.” While inspiring levels of love and hope are found among these amazing families…
Source: NIH Director's BlogCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Neurophet receives FDA clearance for Aqua - 12 month(s) ago
Artificial intelligence software developer Neurophet has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Aqua brain MRI analysis software.
Source: AuntMinnie.comCategories: Healthcare Professionals, Latest HeadlinesTweet
Today’s acquisition of Caraway Therapeutics, Inc. underscores our commitment to developing treatments for #neurodegenerative diseases. Read our news here: https://t.co/fKRTypyWLf https://t.co/uvF0Wx0hLo